A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
OBJECTIVE: In order to investigate whether a central nervous system penetrant anti-inflammatory could augment or sustain obesity treatment with semaglutide (Wegovy), a glucagon-like peptide-1 receptor (GLP-1R) agonist, we tested two hypotheses in mod…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are widely used in the treatment of metabolic disorders, including type 2 diabetes (T2D) and obesity. These medications primarily function by enhancing insulin secretion; howe…
This study aimed to identify the prevalence of prescription weight loss medication use among boys and men, describe the sociodemographic differences between those who did and did not report use, and explore differences in eating disorder attitudes an…
Obesity is a multifactorial, complex disease that is driven by genetic, biological, environmental, and behavioral factors. In this review, we explain the key contributors to obesity, limitations in current definitions, its relationship with cardiomet…
Obesity is a well-established risk factor for perioperative morbidity, including periprosthetic joint infection (PJI) and unplanned readmission following total hip and knee arthroplasty. Glucagon-like peptide-1 (GLP-1) receptor agonists induce clinic…
INTRODUCTION: Sphingolipid metabolism has been implicated in many diseases including cancer, pathologic inflammation, viral infection, neurologic pathologies and metabolic pathologies, including obesity and diabetes. We have previously shown that opa…
Recent randomized controlled trial evidence in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) indicates that adding finerenone to empagliflozin provides additive clinical benefit. A prespecified analysis demonstrates that this ben…
An older woman with dementia and type 2 diabetes was started on semaglutide and subsequently developed severe psychological and physical symptoms, including apathy, significant weight loss and decreased appetite. These symptoms markedly improved afte…
BACKGROUND: The aim of the study was to compare the effectiveness of tirzepatide versus semaglutide in producing weight loss. METHODS: A systematic search was conducted in databases PubMed, Scopus, and Web of Science on January 22, 2025, using search…
BACKGROUND: Dual and triple incretin-based agonists, targeting combinations of GLP-1, GIP, and glucagon receptors, represent an innovative approach in T2DM care. However, comparative efficacy and safety analyses tailored to receptor-specific strategi…
: Patients with type 2 diabetes mellitus (T2DM) and inflammatory bowel disease (IBD) face elevated risk of hepatobiliary complications. The biliary safety of GLP-1 and dual GLP-1/GIP receptor agonists in this population is uncertain.: We conducted a…
: Fatty liver disease and obesity are among the most prevalent health conditions in modern society and have recently garnered significant attention. Semaglutide, a well-known anti-obesity drug, has been widely used for diabetes and obesity treatment;…
BACKGROUND: Reduction of premature death and adverse cardiovascular outcomes is a key goal in type 2 diabetes management. OBJECTIVE: To compare mortality and cardiovascular event risks in patients treated with semaglutide versus empagliflozin and, se…
AIMS: To evaluate the cost-effectiveness of liraglutide, semaglutide, tirzepatide, benaglutide, and lifestyle management for the treatment of obesity from the perspective of the Chinese healthcare system. MATERIALS AND METHODS: This study gathered cl…